The PennZone

International Collaboration Aims to Ensure More Equitable Access to Transformative Personalized Cancer Therapy

PHILADELPHIA, May 23, 2022 /PRNewswire/ -- Penn Medicine and Children's Hospital of Philadelphia (CHOP), who together pioneered the research and development of the world's first personalized cellular therapy for cancer — also known as CAR T cell therapy — have announced plans with Costa Rica's CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to facilitate CAR T research in Costa Rica. The effort is a step toward global equity in clinical research opportunities involving the use of CAR T cell therapies, which represent a leading-edge approach to cancer care not widely available across the world.

More on The PennZone

• Harry Hayman Celebrates Years of WHYY Coverage, Partnership & Shared Commitment to Philadelphia
• Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
• Stockwell Elastomerics expands micro molding capabilities
• Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
• Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026

---

Show All News | Report Violation